Alembic Pharmaceuticals has reported results for first quarter ended June 30, 2024 (Q1FY25).
The company has reported 80.65% rise in net profit at Rs 176.19 crore for Q1FY25 as compared to Rs 97.53 crore for the same quarter in the previous year. Total income of the company increased by 10.01% at Rs 1478.70 crore for Q1FY25 as compared to Rs 1344.12 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 11.70% rise in its net profit at Rs 134.71 crore for the quarter ended June 30, 2024 as compared to Rs 120.60 crore for the same quarter in the previous year. Total income of the company increased by 4.41% at Rs 1563.83 crore for Q1FY25 as compared to Rs 1497.81 crore for the corresponding quarter previous year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1830.20 |
Dr. Reddys Lab | 1183.00 |
Cipla | 1549.65 |
Lupin | 2094.65 |
Zydus Lifesciences | 887.70 |
View more.. |